Alert detail

LCD L36044: MolDX: Genetic Testing for BCR-ABL Negative Myeloproliferative Disease — Palmetto GBA

Policy ID: LCD-L36044Specialty: HematologyAdded: 6/5/2026Effective: July 6, 2023lcd
High

What changed

New guidelines impact billing for genetic tests in myeloproliferative disease.

Who’s affected: Hematology billing teams · Effective: July 6, 2023

Affected codes

Primary source: View the official CMS/MAC document ↗

Get the action steps and full analysis

This change affects 18 billing codes.

Subscribers get the recommended action (“what to do”), the full AI analysis, the LCD revision comparison, and related alerts across your specialty and jurisdiction.

Audit documentation

Building an audit file?

The Tripwire Audit Pack exports 12 months of Hematology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.

Get the Hematology audit pack — $349One-time purchase · not a subscription

Not ready to subscribe?

Get the free weekly reimbursement brief for Hematology— the week’s changes and deadlines, delivered to your inbox. No account required.